(Q39417710)

11 September 2017

title

Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria (English)

1 reference

11 September 2017

main subject

Plasmodium falciparum

0 references

malaria

0 references

multiple drug resistance

1 reference

1 reference

1 reference

Sabchareon A

1

1 reference

11 September 2017

Attanath P

2

1 reference

11 September 2017

Phanuaksook P

3

1 reference

11 September 2017

Chanthavanich P

4

1 reference

11 September 2017

Poonpanich Y

5

1 reference

11 September 2017

Mookmanee D

6

1 reference

11 September 2017

Chongsuphajaisiddhi T

7

1 reference

11 September 2017

Sadler BM

8

1 reference

11 September 2017

Hussein Z

9

1 reference

11 September 2017

Canfield CJ

10

1 reference

11 September 2017

Hutchinson DB

11

1 reference

11 September 2017

publication date

1 March 1998

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

11 September 2017

published in

1 reference

11 September 2017

volume

92

1 reference

11 September 2017

issue

2

1 reference

11 September 2017

page(s)

201-206

1 reference

The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

Oxidative activation of proguanil and dapsone acetylation in Thai soldiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

The multiple dose pharmacokinetics of proguanil

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

Mefloquine-resistant falciparum malaria on the Thai-Burmese border

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

Atovaquone and proguanil for Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

Antimalarial drug resistance: the pace quickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

In vitro activity of atovaquone against the African isolates and clones of Plasmodium falciparum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

7 January 2021

Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

7 January 2021

Atovaquone and proguanil for the treatment of malaria in Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

7 January 2021

Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

7 January 2021

Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2898%2990749-0

7 January 2021

10.1016/S0035-9203(98)90749-0

Identifiers

DOI

1 reference

11 September 2017

1 reference